Completed PHASE2 INTERVENTIONAL 1-arm NCT00949364

Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage

Multi-Center Phase II Study With Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage

Sponsor: University of Ulm

Updated 7 times since 2017 Last updated: Sep 21, 2017 Started: Dec 31, 2009 Primary completion: Dec 14, 2016 Completion: Dec 14, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00949364, this PHASE2 trial focuses on Myeloproliferative Neoplasms and remains completed. Sponsored by University of Ulm, it has been updated 7 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Oct 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jan 2017 — Oct 2017 [monthly]

Unknown Status PHASE2

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Ulm

Data source: University of Ulm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Berlin, Germany , Bonn, Germany , Dresden, Germany , Düsseldorf, Germany , Frankfurt, Germany , Freiburg im Breisgau, Germany , Hamburg Eppendorf, Germany , Jena, Germany , Magdeburg, Germany and 5 more locations